Capricor Therapeutics Inc (CAPR)

[dia76ca]

Steady progress on DMD is great. But the elephant in the room are the partnerships for the Exosome platforms.
Here is what the company has said...
"Exosome-Based Therapeutics and Vaccines (Preclinical): We are focused on developing a precision-engineered exosome platform technology that has the ability to deliver defined sets of effector molecules which exert their effects through defined mechanisms of action. We recently published preclinical data on our StealthXTM platform showing the rapid development of a recombinant protein-based.... At this time, we are developing vaccines and therapeutics for infectious diseases, monogenic diseases and other potential indications. Our platform builds on advances in fundamental RNA and protein science, targeting technology and manufacturing, providing us the opportunity to potentially build a broad pipeline of new therapeutic candidates. Our current strategy is FOCUSED on SECURING PARTNERS who will provide capital and additional resources..."